Supplementary Figure 1 from EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
Year: 2025
Type: supplementary-materials
Abstract: EDIL3 antibody response to Ipi-Bev therapy in metastatic melanoma patients.
Authors: Saba Tabasum, Dinesh Thapa, Anita Giobbie-Hurder, Jason L. Weirather, Marco Campisi, Pieter J. Schol, Xiaoyu Li, Jingjing Li, Charles H. Yoon, Michael P. Manos, David A. Barbie, F. Stephen Hodi
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4416721606
Cites:
Cited by:
Related to: